Objective: We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in patients with pancreatic cancer.
P ancreatic cancer is a major cause of death in Western populations and has a poor prognosis. The median survival after diagnosis is shorter than 6 months, and 5-year survival is 3% to 5%. 1, 2 Surgical resection is the only treatment offering patients with pancreatic cancer cure, but the resectability rate remains at 15% to 20% because the tumor is frequently beyond surgical resectability or has already metastasized when symptoms first appear. 3 The current postresection 5-year survival rate is approximately 20%. 4 Pancreatic cancer is among the best-described genetic diseases. Accumulated genetic alterations in dominant oncogenes, such as Kirsten rat sarcoma (K-ras), and tumor suppressor genes, such as p53, p16 (cyclin-dependent kinase inhibitor 2 [CDKN2]), and DPC4 (SMAD4 or MADH4), are involved in the pathogenesis of pancreatic cancer. 3, 5 The K-ras oncogene is mutated (almost always confined to codon 12) in 75% to 95% of exocrine pancreatic cancers. 6 K-ras mutations provoke an inappropriate stimulation signal and a constitutive growth signal to the nucleus. Alterations of the K-ras gene can be detected in clinical specimens (tissue samples, pancreatic juice, duodenal aspirates, stool, and serum) by different methods such as restriction fragment length polymorphism, single-strand confirmation polymorphism, mutant-specific allele amplification, sequencing, or selective hybridization. 4 Although there have been advances in imaging techniques, diagnosing the disease remains difficult, succeeding normally only in advanced stages of disease. Conventional tumor markers, such as serum carbohydrate antigen 19.9 (CA 19-9), have inadequate diagnostic sensitivity and specificity and are therefore not suited for detecting early-stage tumors. 4 Different studies have reported that plasma K-ras mutation analysis can complete the serum CA 19-9 level determination, provide additional clinically useful information, and detect most cases of pancreatic cancer. 7, 8 A noninvasive prognostic tool with a very high sensitivity and specificity could be extremely helpful to improve the poor prognosis of patients with pancreatic cancer.
According to previous studies, we investigated the presence of K-ras mutations in circulating plasma DNA and assessed its clinical value in patients with pancreatic cancer. Peripheral blood samples of a large series of patients with pancreatic cancer and of controls with pancreatitis were analyzed. We determined the occurrence of K-ras gene alterations in a follow-up study for a period of approximately 2 years (if available). In particular, we investigated the diagnostic value of combined K-ras mutations and serum CA 19-9 levels in patients with pancreatic carcinoma. The detection of K-ras mutations was performed by using the highly sensitive method of the polymerase chain reaction (PCR) clamping approach with melting curve analysis using mutant-specific hybridization probes combined with wild typeYspecific peptide nucleic acids (PNAs). 9 All in all, the aim was to evaluate the prognostic value of the K-ras status in the peripheral blood of patients with pancreatic cancer.
MATERIALS AND METHODS Patients
This study included 56 patients with pancreatic cancer. The median age at initial diagnosis was 59.7 years, and the ORIGINAL ARTICLE 534 | www.pancreasjournal.com male-female ratio was 1.2:1 (31 men and 25 women). Patients were followed up in the period (as possible) from diagnosis to the end of the observation period or death. Twenty-five patients underwent surgical resection, and 23 patients were primarily inoperable (the data of the remaining 8 patients were not available). The median survival of the total patient population (51 patients with known date of initial diagnosis) was 19 months. The median survival of the patients with operable disease was 28 months, whereas the patients with advanced/unresectable pancreatic cancer survived for a median of only 10 months. At the end of the study, all but 5 patients with pancreatic cancer were dead.
A control group of 13 patients with chronic or acute pancreatitis were recruited and included. We collected 1 blood sample from each control patient and performed the K-ras assay.
Plasma DNA
Peripheral venous blood (9 mL) was taken and placed in tubes containing EDTA after informed consent was obtained from the patients and the controls. Samples were taken from the patients with pancreatic cancer (as possible) every 4 weeks after initial diagnosis until the end of the observation period or death. Four hundred seventeen plasma samples of 56 patients with pancreatic cancer and 13 plasma samples of 13 patients with pancreatitis (controls) were collected for analysis of K-ras mutations. Blood samples were centrifuged at 1500 rpm for 10 minutes (Minifuge RF; Heraeus, Hanau, Germany). Plasma was stored at j20-C until further use. DNA was extracted from plasma with QIAamp spin columns (QIAamp DNA Mini Kit; Qiagen, Hilden, Germany) according to the manufacturer's instruction. Incubation with proteinase K was done for 10 minutes at 68-C. Extracted DNA from 200 KL of plasma was eluted with 50 KL and stored at j20-C.
For the determination of CA 19-9 levels, we collected 239 serum samples from 44 of the included patients with pancreatic cancer at the same time as the collection of plasma for K-ras analysis. We correlated the results from the 239 matched samples to determine any relationship between K-ras status and CA 19-9 serum level.
Detection of K-ras Gene Mutations
For detection of the hot spot point mutation of the K-ras proto-oncogene at codon 12, we used PNA-mediated PCR clamping and real-time PCR with mutant-specific hybridization probes. The relative positions of the primers, hybridization probes, and PNA, as well as the high sensitivity (1:100,000, mutantYwild type), of our assay were described elsewhere (GenBank accession No. K01519; nucleotide positions 1Y164). Melting curve analysis was performed at steadily increasing temperature from 40-C to 85-C with a transition rate of 0.3-C/s.
Fluorescence data obtained were analyzed using the LightCycler software (version 3.5; Roche Diagnostics). All synthetic oligonucleotides were purchased from TIB Molbiol (Berlin, Germany).
The PCR experiments were performed at least twice on each sample. The DNA of the cell line SW480 (colon carcinoma) harboring the homozygous K-ras codon 12 GTT mutation was used as a positive control.
Statistical Analysis
Statistical comparisons of the different data between groups (with results positive vs negative for K-ras mutation in plasma) were tested by t test, W 2 test, Monte Carlo exact test, and log-rank test. The Mann-Whitney-Wilcoxon U test was used to correlate the K-ras status in peripheral blood with the serum concentration of CA 19-9. Differences were considered significant when P G 0.05. All calculations were performed by using the Statistical Package for the Social Sciences (SPSS Inc, version 11.0, Chicago, Ill).
RESULTS

K-ras Gene Mutations in Plasma
Adequate DNA was extracted from the plasma in sufficient quantities for analysis in all patients and controls. The concentrations of DNA extracted from the plasma of patients with pancreatic cancer and pancreatitis were determined by spectrophotometry and ranged from 100 to 700 pg per 200 KL of plasma.
Correlation of K-ras Gene Alteration and Clinical Features
K-ras mutations were identified in 20 (36%) of 56 patients with pancreatic cancer and 60 (14%) of 417 plasma samples (Table 1) . We observed alternating results of the K-ras assay in individual patients with cancer during follow-up. Thereby, it is remarkable that K-ras mutations were particularly detected shortly after initial diagnosis and/or before death (Table 1,  patients 5, 8Y10, 17 , 27, 34, 39, 43, 44, and 49). In the intermediate time interval, the detection of K-ras mutations in the peripheral blood was negative (patients 5, 17, 34, 44, and 49) or predominantly persistent (patients 8, 9, 11, and 43). Other patients (3, 6, 24, 28, 35, 36 , 51, and 56) showed isolated positive results for the detection of K-ras mutations in the peripheral blood. The most common alteration in the detectable plasma K-ras mutations (16 of 20 patients) was from wild type GGT (encoding glycine) to GTT (valine). The remaining 4 patients showed a transition different from GTT (nonvaline). Further verification of these point mutations was not done. The DNA from the plasma samples of the control group of 13 patients with chronic or acute pancreatitis were analyzed for K-ras mutations. In 12 patients, no gene alterations were detectable, and for 1 patient, the result was ambiguous (data not shown). The positive predictive value for plasma K-ras mutation detection was 100%, and the negative predictive value was 27%. There were no statistically significant differences in age (P = 0.58), sex (P = 0.28), localization of the tumor in the pancreas (P = 1.00), resectability of the tumor (P = 0.33), and survival (P = 0.10) according to the presence or absence of plasma K-ras mutations (Table 2) .
Plasma K-ras Mutations and CA 19-9
Elevated CA 19-9 levels were found in 35 (80%) of the 44 patients using a cutoff value higher than 37 U/mL and in 30 (68%) of the 44 patients using a cutoff value higher than 100 U/mL. No CA 19-9 values of the patients with pancreatitis used as the control group for the K-ras assay were available. In 7 (35%) of 20 patients with pancreatic cancer or 10 of 86 plasma samples with CA 19-9 levels lower than 100 U/mL, the result of the assay was positive for K-ras mutation. Five of the 7 patients with K-ras variants and CA 19-9 levels lower than 100 U/mL had CA 19-9 levels lower than 37 U/mL. Elevation of either CA 19-9 level (cutoff, 937 U/mL) or the presence of K-ras mutations in plasma was seen in 40 (91%) of the 44 patients. Of the 35 patients with pancreatic cancer and elevated serum levels of the tumor marker CA 19-9 (cutoff, 937 U/mL), 13 (102 plasma samples) with altered K-ras gene showed significant correlation with elevated CA 19-9 levels (median, 552 U/mL; P = 0.048; Fig. 1 ).
DISCUSSION
In the present study, one of the most frequent K-ras gene mutation (valine) observed in pancreatic cancer was analyzed in the plasma of a patient with pancreatic cancer and pancreatitis (controls). Whereas previous studies analyzed 1 sample per individual after diagnosis of pancreatic cancer, we present a study of time course analysis of K-ras gene alterations. The occurrence or absence of K-ras mutations in the peripheral blood might reflect different tumor stages in 1 patient, depending on the time of observation. Therefore, it is anticipated that there are patients who tested positive for the K-ras mutation in some plasma samples and negative in others. Indeed, we observed alternating results of the K-ras Plasma samples (n = 102) of 13 patients with pancreatic cancer with elevated serum levels of the tumor marker CA 19-9 (cutoff, 937 U/mL) and detected K-ras gene alteration in the peripheral blood at least once during the observation period were analyzed regarding correlation between K-ras status and CA 19-9 plasma level. Positive detection of K-ras mutation showed significant correlation with elevated CA 19-9 levels (median, 552 U/mL; P = 0.048). Illustrated is the total observation period (left) and, in addition, 2 time slices (right, dark gray, mutation; light gray, wild type). Outliers are indicated by open dots and asterisks. "Extreme" outliers, or those which lie more than 3 times the interquartile range (IQR) above and below of the first and third quartiles respectively, are indicated by the presence of an asterisk. "Mild" outliers, or those which lie more than 1.5 times the IQR above and below the first and third quartile but are not also extreme outliers are indicated by the presence of an open dot.
assay in individual patients with cancer, with higher incidence after initial diagnosis and before death. These findings indicate that the detection of K-ras mutations in the peripheral blood could reflect the tumor burden of individual patients with pancreatic cancer. Otherwise, isolated positive results for the detection of K-ras mutations in the peripheral blood during follow-up could be a sign of transient hematogenous tumor cell dissemination. However, our study was not designed to investigate the correlation of the detection of K-ras mutations and medical (chemo-)therapies, the results of different imaging modalities, and/or other clinical parameters at consecutive points of time.
Detection of K-ras mutations in circulating DNA had a low sensitivity (36%) but a high specificity (100%) for the diagnosis of pancreatic cancer. The sensitivity was in agreement with previous studies (27%Y81%).
1,5Y8,10Y17 Higher K-ras mutation prevalences have been reported in pancreatic or duodenal juice (63% to 100%) probably owing to the higher amount of tumor DNA in those specimens as compared with the plasma samples. 12,18,19Y24 When combined with CA 19-9, sensitivity was raised to 91% (discussed later). K-ras mutations have been reported in pancreatic tissue or juice from 6% to 42% of patients with chronic pancreatitis. 6 Knowing that a part of this mutated DNA can be released into circulation, our control group included patients with pancreatitis. 7 Even so, we revealed a specificity of 100%. The specificity in other analogue studies ranged from 87% to 100%, depending on the quantity and quality of the control group. 1, 6, 10, 16, 17 Serum CA 19-9 is one of the most commonly used tumor markers for pancreatic cancer diagnosis, with sensitivity in the range of 58% to 87%. 4 This marker is not informative in 5% of the population who cannot express CA 19-9 because of a Lewis negative status. 25 However, serum CA 19-9 lacks specificity (70%Y80%). 6 Serum CA 19-9 levels may also be raised in other malignancies, such as adenocarcinoma of the stomach, colon, and the hepatobiliary system, and in obstructive jaundice, acute cholangitis, and worst of all, in chronic pancreatitis. 26 In the present study, serum CA 19-9 had good sensitivity (80%). The incidence of 35% (7/20 patients) of positive K-ras detection in plasma at a time of nonelevated CA 19-9 levels suggests that the analysis of the K-ras status can identify patients with pancreatic cancer who have lower CA 19-9 levels than are usually associated with this cancer. Other studies show an even higher incidence of 71% (25/35 patients): Yamada et al, 7 3 of 6 patients; Dianxu et al, 8 12 of 17 patients; Theodor et al, 10 6 of 7 patients; and Sorenson et al, 14 4 of 5 patients. The absence of K-ras mutations and the abnormal CA 19-9 levels made the diagnosis of pancreatic cancer unlikely. Thus, the combination of both tests, that is, the detection of K-ras alterations in the DNA of peripheral blood and the determination of CA 19-9 level, could be useful to assess cancer diagnosis in patients with normal or, because of individual genetic alterations for Lewis enzyme expression, noncontributive CA 19-9 levels and also to provide additional supportive information.
In the present study, the occurrence of K-ras mutations in peripheral blood was not correlated with age, sex, tumor site, resectability of the tumor, and survival. These results are in agreement with other studies. Uemera et al 5 found no associations between K-ras mutations in the plasma DNA and age, sex, size of the tumor, stage of disease, or presence of metastasis. Maire et al 6 found that the presence of K-ras mutations in serum was not correlated with age, sex, smoking habit, or tumor stage. Three other studies in the literature are in agreement with these results, but Castells et al 1 have reported a statistically significant relation between circulating DNA K-ras alterations and survival time. 7, 8, 10 Early diagnosis of pancreatic carcinoma is extremely difficult. Plasma DNA is a reliable source for K-ras gene mutation analysis. Our approach of noninvasive, convenient, extremely highly sensitive K-ras mutation analysis in plasma might provide diagnostic and prognostic information to clinicians. The combination with CA 19-9 assay is useful for the detection and prognostic evaluation of pancreatic carcinoma. Larger studies are required to assess the significance of our findings to clinical practice.
